UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 8.

Kros, J M; Huizer, K; Hernandez-Lain, A; Marucci, G; Michotte, A; Pollo, B; Rushing, E J; Ribalta, T; French, P; Jamine, D; Bekka, N; Lacombe, D; van den Bent, M J; Gorlia, T (2015). Evidence-based diagnostic algorithm for glioma: analysis of the results of pathology panel review and molecular parameters of EORTC 26951 and 26882 trials. Journal of Clinical Oncology, 33(17):1943-1950.

Douzgou, S; Clayton-Smith, J; Gardner, S; Day, R; Griffiths, P; Strong, K; Amiel, J; Baraitser, M; Brueton, L; Brunner, H; Chrzanowska, K; Dallapiccola, B; Del Campo Casanelles, M; Devriendt, K; Donnai, D; Fitzpatrick, D; Gillessen-Kaesbach, G; Houge, G; Kerr, B; Krajewska-Walasek, M; Lacombe, D; Meinecke, P; Metcalfe, K; Mortier, G; Odent, S; Philip, N; Prescott, T; Raas-Rothschild, A; Rauch, A; Rittinger, O; Salonen, R; Schrander-Stumpel, C; Suri, M; Temple, K; Tolmie, J; Van Der Burgt, I; Verloes, A; Wieczorek, D; Zenker, M (2014). Dysmorphology at a distance: results of a web-based diagnostic service. European Journal of Human Genetics, 22(3):327-332.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; Macdonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2013). Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 126(1):159.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; McDonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2012). MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 124(4):547-560.

Weller, M; Gorlia, T; Cairncross, J G; van den Bent, M J; Mason, W; Belanger, K; Brandes, A A; Bogdahn, U; Macdonald, D R; Forsyth, P; Rossetti, A O; Lacombe, D; Mirimanoff, R-O; Vecht, C J; Stupp, R (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 77(12):1156-1164.

Holman, S K; Daniel, P; Jenkins, Z A; Herron, R L; Morgan, T; Savarirayan, R; Chow, C W; Bohring, A; Mosel, A; Lacombe, D; Steiner, B; Schmitt-Mechelke, T; Schroter, B; Raas-Rothschild, A; MiƱaur, S G; Porteous, M; Parker, M; Quarrell, O; Tapon, D; Cormier-Daire, V; Mansour, S; Nash, R; Bindoff, L A; Fiskerstrand, T; Robertson, S P (2011). The male phenotype in osteopathia striata congenita with cranial sclerosis. American Journal of Medical Genetics. Part A, 155(10):2397-2408.

Stupp, R; Hegi, M E; Mason, W P; van den Bent, M J; Taphoorn, M J B; Janzer, R C; Ludwin, S K; Allgeier, A; Fisher, B; Belanger, K; Hau, P; Brandes, A A; Gijtenbeek, J; Marosi, C; Vecht, C J; Mokhtari, K; Wesseling, P; Villa, S; Eisenhauer, E; Gorlia, T; Weller, M; Lacombe, D; Cairncross, J G; Mirimanoff, R O (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, 10(5):459-466.

Gorlia, T; van den Bent, M J; Hegi, M E; Mirimanoff, R O; Weller, M; Cairncross, J G; Eisenhauer, E; Belanger, K; Brandes, A A; Allgeier, A; Lacombe, D; Stupp, R (2008). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncology, 9(1):29-38.

This list was generated on Fri Jul 21 03:54:46 2017 CEST.